A Phase 4 interventional study of Dinalbuphine Sebacate and Normal Saline in Osteo Arthritis of the Knee and Total Knee Anthroplasty, sponsored by Thammasat University. Not yet recruiting at 1 site in Thailand. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Thammasat University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing nalbuphine sebacate in Pain, Postoperative — 3 open to participants now, 3 under way, 1 of them phase 3. nalbuphine sebacate · Pain, Postoperative.
Among the 11 studies testing nalbuphine sebacate in Pain, Postoperative, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 4, and was the 11th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 11 studies testing nalbuphine sebacate in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
Dalin Tzu Chi General Hospital · Sites in Taiwan
Ages 20+ · Women only
Sinew Pharma Inc. · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3 · Phase 4 6
First in 2017; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 78 across the 11 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 9 most frequent:
Thammasat University is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
11 studies in Pain, Postoperative by Thammasat University: 2 open now, 2 under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 11 studies in Pain, Postoperative by Thammasat University, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 4, and was the 10th registered.
Thammasat University’s Pain, Postoperative studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing nalbuphine sebacate in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Thammasat University’s 11 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty
A single dose of intramuscular Dinalbuphine Sebacate can mitigate pain for up to 1 week after TKA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Naldebain 150mg/2mL IM
Drug: Dinalbuphine Sebacate
Normal saline 2 mL IM
Drug: Normal Saline
Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA
Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block
Visual analog scale for pain (VAS 0-100)
Visual analog scale for pain at rest and on motion (knee flexion 90 degrees) using 0-100 mm, where a score of 0 represented no pain and 100 indicated the most severe pain
Time frame: Record every 12 hours after surgery until 2 weeks postoperatively, then once weekly until 12 weeks postopertively
The amount of analgesic drug used
The amount of IV morphine and oral tramadol (milligram)
Time frame: During hospitalization and at home until 12 weeks after surgery
Adverse effects
Incidence of adverse effects including pyrexia, nausea, vomiting, dizziness, injection site pain, and somnolence
Time frame: The first week after surgery
Length of stay
Length of stay (day)
Time frame: During hospitalization (from admission to discharge)
Modified WOMAC score
Modified Western Ontario and McMaster Universities Osteoarthritis Index score, including total \& subscore. Each item was scored with a Likert scale (0-4). The overall MOWAC was 0-96 (high score = worse symptoms)
Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively
Forgotten Joint Score
Forgotten Joint Score (Thai version) with 12 questions. Each item was scored on a Likert scale (0-4). The raw score was converted to a 0-100 scale (0 = worst, 100 = best)
Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively
Time up and go (TUG) test
Time up and go (TUG) test records the time in seconds when the patient starts standing up from the chair, then walks 3 meters at a normal pace, and turns around to sit on the chair.
Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively
Knee range of motion
Angle of knee flexion and extension in degrees using a long goniometer
Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively
Rate of closed manipulation
Closed manipulation under anesthesia due to an unsatisfactory range of motion
Time frame: At 3 months postoperatively
Plan to share: Undecided
Start is estimated for Oct 2025; primary completion for Jun 2026, 8 months later.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 8 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine sebacate
Thammasat University